Sunnybrook Health Sciences Centre, Division of Psychiatry, University of Toronto, Toronto, ON, Canada.
Clinical Laboratory and Diagnostic Services, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Mult Scler. 2021 Apr;27(4):636-639. doi: 10.1177/1352458520934070. Epub 2020 Jun 26.
To assess whether symptoms of depression change when people with multiple sclerosis (pwMS) discontinue cannabis use, 40 cognitively impaired pwMS who smoked cannabis almost daily were randomly assigned to either a cannabis continuation (CC) or cannabis withdrawal (CW) group. Both groups were followed for 28 days. All participants completed the Hospital Anxiety and Depression Scale. At day 28 the 11-nor-9-carboxy-Δ-tetrahydro-cannabinol (THCCOOH)/creatinine ratio in the CW group declined to zero ( = 0.0001), but remained unchanged in the CC group ( = 0.709). Depression scores in those pwMS who were using cannabis to manage their depression remained statistically unchanged in the CC group, but declined in the CW group ( = 0.006). Despite pwMS using cannabis to help their mood, depression improved significantly off the drug. Our finding provides a cautionary note in relation to cannabis use in pwMS, at least with respect to depression.
为了评估多发性硬化症（pwMS）患者停止使用大麻时抑郁症状是否会发生变化，40 名认知受损且几乎每日吸食大麻的 pwMS 被随机分配至大麻继续使用（CC）或大麻戒断（CW）组。两组均随访 28 天。所有参与者都完成了医院焦虑和抑郁量表。在第 28 天，CW 组的 11-去甲-9-羧基-Δ-四氢大麻酸（THCCOOH）/肌酐比值降至零（ = 0.0001），而 CC 组则保持不变（ = 0.709）。在 CC 组中，那些使用大麻来控制抑郁症状的 pwMS 的抑郁评分保持不变，但在 CW 组中则下降（ = 0.006）。尽管 pwMS 使用大麻来改善情绪，但停药后抑郁症状明显改善。我们的发现为 pwMS 使用大麻提供了一个警示，至少在与抑郁有关的方面是如此。
